HAIFA, Israel, May 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Katherina Reiche, Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety, and Prof. Dr. Hans-Dieter Volk, Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin Germany, met with Pluristem's management and scientists on May 22, 2013. Meetings were held at the company's new manufacturing and R&D headquarters in Haifa, Israel to discuss new opportunities to strengthen existing collaborations Pluristem has with the BCRT and other German clinical research facilities. Zami Aberman, Pluristem's Chairman and CEO, stated, "Pluristem has enjoyed a longstanding relationship with the BCRT, one of Germany's leading translational research institutions, who has conducted research for several indications using our PLX cells. We were fortunate that State Secretary Ms. Reiche and Prof. Dr. Volk were able to visit our new facility and discuss expanding our existing, valuable association in Germany." Prof. Volk stated, "The BCRT values the affiliation we have with Pluristem and look forward expanding this collaboration in the future utilizing their exciting, innovative PLX technology." Parliamentary State Secretary Ms. Reiche stated, "Pluristem´s collaboration with BCRT is a path-breaking example of how cutting edge technologies can be translated into innovative therapies and applications. The intelligent investment in Germany and Israel into infrastructure, research and products pays off for the benefit of patients." About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882 Safe Harbor Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we discuss the opportunities discussed with the German federal ministry and the Charite Berlin-Brandenburg Center, to strengthen and expand existing collaborations, we are using forward-looking statements. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
CONTACT: Pluristem Therapeutics Inc.: William Prather R.Ph., M.D. Sr. VP Corporate Development 1-303-883-4954 William.PratherMD@pluristem.com Daya Lettvin Investor & Media Relations Director +972-54-674-5580 firstname.lastname@example.org